Zealand Pharma Shares Fall After Weight-Loss Drug Trial Setback

Zealand Pharma's shares dropped significantly by 32% following disappointing mid-stage trial results for a weight-loss treatment being developed with Roche.

6 Mar, 10:24 — 6 Mar, 13:52

Post Share

Why this matters

The pharmaceutical industry heavily invests in the development of new weight-loss drugs, a highly competitive and lucrative market. A setback for one company can impact investor confidence across the sector and shift the competitive landscape for other drug developers.

Key entitiesZealand Pharma Roche

The Story

What 2 sources agree on, dispute, and miss

What sources agree on

Zealand Pharma's shares fell significantly
The decline was due to disappointing results from a Phase 2 trial of its weight-loss drug

Key claims1 agreed · 2 unverified

✓

Zealand Pharma's obesity drug showed disappointing weight loss in a Phase 2 trial

agreed·marketwatchFT

Zealand Pharma's shares fell 32%

unverified·FT

The treatment is being developed with Roche

unverified·FT

Coverage gaps

The specific percentage of Zealand Pharma's share price fall (32%) and its collaboration with Roche on the drug

ReportedFT

Missingmarketwatch

The Story

Analyzing sources…

Source Diversity

Low (24/100)

2 sources— more sources would strengthen this score15/33

Spectrum spread— 1/5 buckets covered0/33

Far L

Left

Center2

Center (2)

marketwatchFT

Right

Far R

Geographic diversity— 2 regions9/34

US1UK1

ℹOnly 2 sources cover this story

Political spectrum

LeftCenterRight

marketwatch

Outlet rating This story

SourceOutletiGeneral editorial lean of the outletStoryiHow they covered this specific storyToneFactuality

marketwatchcentercenterneutralMostly Factualfactual reporting on financial news

FTcentercenteranalyticalVery Highobjective reporting on biotech and market impact

Coverage leans: balanced

Both outlets provide straightforward, factual reporting on the financial and pharmaceutical news without apparent political leanings.

Sources

Showing 2 of 2 sources

FTVery High173d ago

Biotech group’s shares hit by weight-loss drug setback

Zealand Pharma falls 32% following mid-stage trial results for treatment being developed with Roche

Read full article →

marketwatchMostly Factual172d ago

Disappointing weight-loss-drug trial results from Zealand Pharma send shares tumbling

Zealand Pharma obesity drug showed disappointing weight loss in a Phase 2 trial.

By Jaimy Lee

Read full article →

Coverage Timeline

First report: FT · 6 Mar, 10:24|Full coverage: 2 · 3h|Window: 3h

Left-leaningCenterRight-leaning

FT6 Mar, 10:24First to report

Biotech group’s shares hit by weight-loss drug setback

3h later

marketwatch6 Mar, 13:52Latest update

Disappointing weight-loss-drug trial results from Zealand Pharma send shares tumbling

Story evolution

Initial ReportingMarch 6 morning

Financial Times first reported the share drop and trial setback, including specific details about the percentage fall and partner.

Broader CoverageMarch 6 afternoon

MarketWatch followed with a more general report on the disappointing trial results and tumbling shares.

PERSPECTA

PERSPECTA

Zealand Pharma Shares Fall After Weight-Loss Drug Trial Setback

Why this matters

The Story

What sources agree on

Key claims1 agreed · 2 unverified

Coverage gaps

The Story

Source Diversity

Source Diversity

Political spectrum

Sources

Biotech group’s shares hit by weight-loss drug setback

Disappointing weight-loss-drug trial results from Zealand Pharma send shares tumbling

Coverage Timeline

Biotech group’s shares hit by weight-loss drug setback

Disappointing weight-loss-drug trial results from Zealand Pharma send shares tumbling

Story evolution

Related Stories

U.S. Inflation Remains Sticky in July, Raising Odds of Federal Reserve Rate Hikes

DAZN Acquires EverPass Media to Expand U.S. Sports Streaming Operations

Williams-Sonoma and Bath & Body Works Upgrade Full-Year Guidance After Strong Quarter

Metlen Expands European Battery Energy Storage Operations

PERSPECTA

Why this matters

Political spectrum

Story evolution

The Story

What sources agree on

Key claims1 agreed · 2 unverified

Coverage gaps

Coverage matrix